Holbrook Jonathan, Lara-Reyna Samuel, Jarosz-Griffiths Heledd, McDermott Michael
Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, UK.
Leeds Institute of Medical Research at St. James's, Leeds, UK.
F1000Res. 2019 Jan 28;8. doi: 10.12688/f1000research.17023.1. eCollection 2019.
The master pro-inflammatory cytokine, tumour necrosis factor (TNF), has been shown to modulate multiple signalling pathways, with wide-ranging downstream effects. TNF plays a vital role in the typical immune response through the regulation of a number of pathways encompassing an immediate inflammatory reaction with significant innate immune involvement as well as cellular activation with subsequent proliferation and programmed cell death or necrosis. As might be expected with such a broad spectrum of cellular effects and complex signalling pathways, TNF has also been implicated in a number of disease states, such as rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. Since the time of its discovery over 40 years ago, TNF ligand and its receptors, TNF receptor (TNFR) 1 and 2, have been categorised into two complementary superfamilies, namely TNF (TNFSF) and TNFR (TNFRSF), and 19 ligands and 29 receptors have been identified to date. There have been significant advances in our understanding of TNF signalling pathways in the last decade, and this short review aims to elucidate some of the most recent advances involving TNF signalling in health and disease.
主要促炎细胞因子肿瘤坏死因子(TNF)已被证明可调节多种信号通路,具有广泛的下游效应。TNF通过调节多种信号通路在典型免疫反应中发挥至关重要的作用,这些信号通路包括涉及显著固有免疫参与的即时炎症反应以及随后的细胞增殖、程序性细胞死亡或坏死的细胞活化。鉴于TNF具有如此广泛的细胞效应和复杂的信号通路,它也与许多疾病状态有关,如类风湿性关节炎、强直性脊柱炎和克罗恩病。自40多年前被发现以来,TNF配体及其受体,即TNF受体(TNFR)1和2,已被归类为两个互补的超家族,即TNF(TNFSF)和TNFR(TNFRSF),迄今为止已鉴定出19种配体和29种受体。在过去十年中,我们对TNF信号通路的理解取得了重大进展,本简短综述旨在阐明一些涉及健康和疾病中TNF信号传导的最新进展。